We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Compounding ban 'a significant public health concern'.
- Abstract
The Australian Society of Compounding Pharmacists (ASCP) has expressed concern over the government's plan to ban the compounding of glucagon-like peptide-2 receptor agonist (GLP-1RA) medications, stating that it will limit patient access to weight loss treatments. The ASCP suggests focusing on individuals who fail to adhere to guidelines on good manufacturing practice and sterile compounding, rather than implementing a blanket ban. They propose alternative options such as audits, inspections, and certifications to ensure compliance. On the other hand, the Society of Hospital Pharmacists of Australia supports the ban, and obesity and diabetes expert Professor Michael Cowley agrees, stating that compounded versions of drugs may not be as safe and effective as approved versions.
- Subjects
PUBLIC health; CURRENT good manufacturing practices
- Publication
Australian Journal of Pharmacy, 2024, Vol 105, Issue 1240, p12
- ISSN
0311-8002
- Publication type
Article